Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CG Oncology, Inc. (CGON : NSDQ)

• Company Description    CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $64.25 Daily Weekly Monthly 20 Day Moving Average: 849,252 shares Shares Outstanding: 88.20 (millions) Market Capitalization: $5,666.98 (millions) Beta: 0.41 52 Week High: $75.50 52 Week Low: $23.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.07% -12.56% 12 Week 14.51% 5.86% Year To Date 54.75% 43.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3000 PEGASUS PARK DRIVE SUITE 1640 - DALLAS,TX 75247 USA ph: 949-409-3700 fax: - ir@cgoncology.com https://cgoncology.com

• General Corporate Information    Officers Arthur Kuan - Chief Executive Officer and Chairman Jim DeTore - Interim Principal Financial and Accounting Officer Susan Graf - Director Brian Liu - Director James J. Mule - Director Peer Information CG Oncology, Inc. (CORR.) CG Oncology, Inc. (RSPI) CG Oncology, Inc. (CGXP) CG Oncology, Inc. (BGEN) CG Oncology, Inc. (GTBP) CG Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 156944100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 88.20 Most Recent Split Date: (:1) Beta: 0.41 Market Capitalization: $5,666.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.70 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 51.32% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.19 Price/Cash Flow: - Price / Sales: 8,560.39 EPS Growth vs. Year Ago Period: -57.78% vs. Previous Quarter: -39.22% Sales Growth vs. Year Ago Period: 1,982.69% vs. Previous Quarter: -53.36% ROE 03/31/26 - -23.33 12/31/25 - -22.87 09/30/25 - -21.67 ROA 03/31/26 - -22.24 12/31/25 - -21.82 09/30/25 - -20.79 Current Ratio 03/31/26 - 31.30 12/31/25 - 24.63 09/30/25 - 22.79 Quick Ratio 03/31/26 - 31.25 12/31/25 - 24.58 09/30/25 - 22.74 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -3,682.61 12/31/25 - -3,985.02 09/30/25 - -6,967.98 Book Value 03/31/26 - 12.38 12/31/25 - 9.33 09/30/25 - 9.02 Inventory Turnover 03/31/26 - 6.68 12/31/25 - 6.06 09/30/25 - 4.20 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.27 12/31/25 - 0.40 09/30/25 - 0.43

Powered by Zacks Investment Research ©